ESMO Immuno-Oncology 2025 | How can immunotherapy refractory melanoma be treated in the clinic?
Inge Marie Svane, MD, PhD, Herlev University Hospital, Herlev, Denmark, discusses the challenges in treating patients with melanoma who do not benefit from first-line checkpoint inhibitor therapies. Various combination therapies are available, including anti-LAG3 with nivolumab and ipilimumab with nivolumab, and the choice of therapy depends on factors such as metastatic situation, PD-L1 expression, and performance status. This interview took place at 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so the talk was about the major issue that we have in melanoma now, that we have very good first-line therapies with checkpoint inhibitors, but it’s not all patients who actually benefit from it. So what are we going to do with those patients? And we have at the moment several combinations for melanoma, both the anti-LAG3 in combination with nivolumab and also the ipilimumab and nivolumab...
Yeah, so the talk was about the major issue that we have in melanoma now, that we have very good first-line therapies with checkpoint inhibitors, but it’s not all patients who actually benefit from it. So what are we going to do with those patients? And we have at the moment several combinations for melanoma, both the anti-LAG3 in combination with nivolumab and also the ipilimumab and nivolumab. And which one are we going to choose? And that depends not only on the metastatic situation, but also like parameters like PD-L1 expression, if they have brain metastasis, if they have poor performance status and so on. So we normally, for the majority of patients, we pick a combination therapy first line. And if they’re not tolerable for the patient, we use monotherapy with anti-PD-1. But after that, we need to have some new good choices also. Yeah.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
